Fig. 8: Antitumor effect of HS201-PDT against various types of human BC xenografts in SCID-beige mice.

a Antitumor effect of HS201-PDT against BT474M1 tumors in vivo. HS201-PDT was performed against BT474M1 tumors (luminal B, ER+, HER2+) in female SCID-beige mice in the same way as indicated in Fig. 7a. As controls, no treatment group, HS201 administration alone group, and a group of laser irradiation without PS administration were made. Averages ± SEM of tumor volume for each group (n = 7 for no treatment group, n = 7 for HS201 alone group, n = 6 for laser alone group, and n = 8 for HS201-PDT group) are shown. Kruskal–Wallis test and nonparametric Dunnett’s test performed. Red arrows indicate laser exposures. b Antitumor Effect of HS201-PDT against patient derived HCI-013 tumors in vivo. HS201-PDT was performed against patient derived xenograft, HCI-013 tumors (invasive lobular, ER+, HER2−), as described in Fig. 7a. No treatment group and laser alone group were set as control groups. Averages ± SEM of tumor volume for each group (n = 8 for no treatment group, n = 7 for laser alone group, and n = 10 for HS201-PDT group) are shown. ANOVA and Dunnett’s test performed. Red arrows indicate laser exposures. c Antitumor effect of HS201-PDT against KPL4 tumors in vivo. HS201-PDT was performed against KPL-4 tumors (inflammatory, HER2+) as described in Fig. 7a. No treatment group, HS201 administration alone group, and laser alone group were compared. Averages ± SEM of tumor volume for each group (n = 8 for no treatment group, n = 7 for HS201 alone group, n = 7 for laser alone group, and n = 7 for HS201-PDT group, respectively) are shown. ANOVA and Dunnett’s test performed. Red arrows indicate laser exposures. d Antitumor Effect of HS201-PDT against KPL4 tumors at their late phase in vivo. HS201-PDT was performed against bulky KPL-4 tumors (over 600 mm³ in volume) on SCID-beige mice in the same way as indicated in Fig. 7a. Individual tumor volumes are shown. Red arrows indicate laser exposures.